Tag: DESTINY-Breast05

Practice-Changing Advances in Early HER2-Positive Breast Cancer: ASCO 2026 and FDA Approvals Establish Trastuzumab Deruxtecan as a New Standard

Compelling evidence presented at the European Society of Medical Oncology (ESMO) Congress, being held October 17-21, 2025, in Berlin, Germany, has shown that a new generation of antibody-drug conjugates (ADCs) can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer.